Form 4: 10x Genomics CEO Gifts Shares, Details Holdings

10x Genomics CEO Serge Saxonov reported a gift of 900 Class A Common Stock shares and detailed various beneficial ownership holdings.

Summary

• Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc. (TXG), reported changes in his beneficial ownership of company securities.
• On September 12, 2025, Saxonov disposed of 900 shares of Class A Common Stock through a gift transaction.
• Following this transaction, his direct beneficial ownership of Class A Common Stock stands at 1,034,817 shares.
• Indirect beneficial ownership of Class A Common Stock includes 27 shares held by the Andromeda Trust, 0 shares by the Sirius Trust (following a transfer), 213,250 shares by the Y/S Descendants' Trust, and 58,000 shares by the Y/S Pot Trust.
• Saxonov directly holds 1,192,040 shares of Class B Common Stock, which are convertible into Class A Common Stock on a one-for-one basis.
• Indirect beneficial ownership of Class B Common Stock includes 89,825 shares held by the Sirius Trust and 1,750,000 shares held across seven other irrevocable trusts.
• Earlier transfers on July 18, 2025, involved 89,825 shares of Class A Common Stock being transferred to Saxonov directly and 89,825 shares of Class B Common Stock being transferred to the Sirius Trust.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (a gift) which is a small disposition relative to total holdings. It does not provide information that would significantly alter the perception of the company's financial health or strategic direction, thus indicating a neutral sentiment.

Positives

• The continued substantial direct and indirect holdings by the CEO demonstrate significant alignment with shareholder interests.

Negatives

• The disposition of 900 Class A Common Stock shares via gift represents a decrease in direct beneficial ownership by the CEO. While a small amount, any insider selling or gifting can be perceived as a slight negative signal, though often for personal financial planning.

Risks

• No specific company operational or financial risks are disclosed in this Form 4 filing. The filing solely reports changes in beneficial ownership by an insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape for 10x Genomics, Inc.

Related Party Transactions

• Transfer of 89,825 shares of Class A Common Stock to the Reporting Person on July 18, 2025, from the Sirius Trust, for which the Reporting Person serves as trustee.
• Transfer of 89,825 shares of Class B Common Stock to the Sirius Trust on July 18, 2025, for which the Reporting Person serves as trustee.
• Beneficial ownership of 27 Class A Common Stock shares held by the Andromeda Trust, for which the Reporting Person serves as trustee.
• Beneficial ownership of 213,250 Class A Common Stock shares held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
• Beneficial ownership of 58,000 Class A Common Stock shares held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
• Beneficial ownership of 1,750,000 Class B Common Stock shares held by Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust, for which the Reporting Person is the sole trustee.

Stakeholder Impact

• Shareholders: Minimal direct impact as the transaction is a small personal gift by the CEO and does not reflect operational or financial performance. The CEO maintains substantial direct and indirect ownership, aligning his interests with shareholders.
• Employees, Customers, Suppliers, Creditors: No discernible impact as this filing pertains solely to an insider's personal stock ownership changes.

Key Dates

Keywords

10x Genomics, TXG, Serge Saxonov, Form 4, Insider Transaction, Beneficial Ownership, Stock Gift, CEO